Arthneeti
Latest: Viyash Scientific Ltd Q1 FY27 results →All Q3 FY26 results →
VS

Viyash Scientific Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Viyash Scientific Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹276
Market cap₹11.2K Cr
P/E50.8
Updated23 Aug 2026
Read4 min read

The short version

The company targets maintaining a revenue mix of approximately 55% formulation and 45% API/CDMO, with both segments expected to show similar growth, supported by CDMO compensating slower growth in regular APIs. The company targets a 15%-20% CAGR growth in EBITDA over the next 3-5 years, with occasional spikes due to acquisitions.

From Viyash Scientific Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets maintaining a revenue mix of approximately 55% formulation and 45% API/CDMO, with both segments expected to show similar growth, supported by CDMO compensating slower growth in regular APIs.
  • Over the next 3-5 years, the Animal Health formulation business is expected to grow significantly, particularly in the companion animal segment driven by increasing pet ownership and genericization.
  • CDMO business is projected to grow substantially, particularly after 2-3 years, once commercial supply of lifecycle management products ramps up.
  • Animal Health APIs are anticipated to grow very fast starting next year, backed by infrastructure and process improvements.

2 more points from Viyash Scientific Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Viyash Scientific Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company plans capital investment in both R&D and manufacturing infrastructure, either through acquisitions or organic expansion in India.
  • Focus on expanding front-end presence with products in strong markets like Europe (Italy, Germany, France, UK, Spain).
  • Exploring growth opportunities via mergers and acquisitions, especially in emerging markets including India and Europe.
  • Intends to build new manufacturing sites for CDMO focused on complex products.
  • Current debt levels are manageable; free cash flow generation expected to support organic growth and acquisitions.
  • Considering leveraging balance sheet and potential share swaps for long-term sustainable growth.
  • Investment to accelerate companion animal business, particularly in India and key European markets.

2 more points from Viyash Scientific Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Viyash Scientific Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The following points provide some context related to order flow and business outlook: - CDMO business saw timing-related variations in quarterly revenues; some contracts shifted sales and validation supplies to next quarters. - CDMO revenue for the year is expected around INR 70-90 crores, with new products and life cycle management projects expected to commercialize next year. - Growth areas such as Animal Health formulations and CDMO are showing increasing inquiries and RFQs, indicating a growing order pipeline.

2 more points from Viyash Scientific Ltd's call on order book

Create a free account to keep reading this call

Viyash Scientific Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Viyash Scientific Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules Ltd (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharmaceuticals Ltd (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Viyash Scientific Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Viyash Scientific Ltd Q3 FY26 results?

The company targets maintaining a revenue mix of approximately 55% formulation and 45% API/CDMO, with both segments expected to show similar growth, supported by CDMO compensating slower growth in regular APIs. The company targets a 15%-20% CAGR growth in EBITDA over the next 3-5 years, with occasional spikes due to acquisitions.

What is Viyash Scientific Ltd share price analysis?

Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹11,246 Cr. Investors should review the full earnings analysis for detailed insights.

Is Viyash Scientific Ltd planning capital expenditure?

The company plans capital investment in both R&D and manufacturing infrastructure, either through acquisitions or organic expansion in India.

Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.